Sorrento TherapeuticsSRNE
13F holders, Q1 2025 (March 31)4holders −1
1new positions
3sold out
$0.00avg. 13F price*
At the end of Q1 2025, 4 institutions reported holding Sorrento Therapeutics Inc. (SRNE) in their 13F filings, down 1 from Q4 2024. 1 opened new positions and 3 sold out. The largest holders were Huntington National Bank ($4), Vermillion Wealth Management, Inc. ($0) and Financial Gravity Asset Management, Inc. ($0).
- Company
- Sorrento Therapeutics Inc.
- CUSIP
- 83587F202
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $0 |
| Exits | 3 | $62 |
All 13F filers, Q4 2024 → Q1 2025: 570 shares bought and 139,700 shares sold, net −139,130 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Huntington National Bank | 0.00% | No change | 5,001 | $4 |
| Vermillion Wealth Management, Inc. | 0.00% | New | 70 | $0 |
| Financial Gravity Asset Management, Inc. | 0.00% | — | 18 | $0 |
| Flagship Wealth Advisors, LLC | 0.00% | Add +100.0% | 1,000 | $0 |
"% of holder's portfolio" is SRNE's weight in each manager's 13F, not the share of Sorrento Therapeutics Inc. the manager owns.